Three items verified; placeholders removed.

Verified

  • Ziftomenib — KURA: FDA approved Nov 13.

  • Plozasiran — ARWR: PDUFA Nov 18.

  • Avance® Nerve Graft — AXGN: PDUFA Dec 5.

Removed/Deferred (TBD pending primary sources)

  • Rocatinlimab (AMG 451)

  • Nirsevimab

  • Mitapivat (timing clarified to ASH Dec 6–9; separate PDUFA timing under reconfirmation)

  • PRAX-628 (conference data only; next topline 1H 2026)

  • Palazestrant/OP-1250 (SABCS trial-in-progress poster; non-binary)

We’ve updated the live list accordingly. Back to regular cadence on Monday.

Keep Reading

No posts found